title: Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features.
abstract: Several studies have demonstrated the potential prognostic importance of angiogenesis in chronic lymphocytic leukemia (CLL). Elevated expression of angiopoietin-2 (Ang-2), an angiogenic cytokine, was recently reported in CLL. However, data regarding prognostic significance of Ang-2 in CLL are limited. Therefore, we quantitated Ang-2 mRNA in purified mononuclear cells of 33 untreated CLL patients and compared the transcript levels to traditional as well as modern prognostic factors in patients with CLL (clinical stage, disease course, IgVH mutation status, CD38, and ZAP-70 expression). Elevated Ang-2 mRNA concentrations were detected in 12 cases; 21 patients had very low or undetectable levels of Ang-2 transcript. There was significant association between high Ang-2 mRNA levels and unmutated IgVH genes (n=27, P=0.010) and with CD38 expression (n=32, P=0.011), but not with ZAP-70 expression (n=32, P=0.784), Rai stage (n=33, P=0.305) or stable versus progressive clinical course (n=33, P=0.443). There was a trend towards shorter progression-free survival in patients with high Ang-2 expression; however, it did not reach statistical significance (P=0.090). Our pilot data show that Ang-2 mRNA is differentially expressed in patients with CLL and its increased expression appears to be associated with poor prognostic features. Further studies are needed to confirm the results in a larger patient cohort.
authors.affiliation: 2nd Department of Internal Medicine, Department of Clinical Hematology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic. vrbacky@fnhk.cz
authors.forename: F
authors.initials: F
authors.lastname: Vrbacky
authors.forename: L
authors.initials: L
authors.lastname: Smolej
authors.forename: V
authors.initials: V
authors.lastname: Vroblova
authors.forename: S
authors.initials: S
authors.lastname: Pekova
authors.forename: M
authors.initials: M
authors.lastname: Hrudkova
authors.forename: M
authors.initials: M
authors.lastname: Cervinka
authors.forename: M
authors.initials: M
authors.lastname: Pecka
authors.forename: J
authors.initials: J
authors.lastname: Krejsek
authors.forename: J
authors.initials: J
authors.lastname: Maly
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000097:blood / Q000378:metabolism; D000328:Adult; D000368:Aged; D042702:Angiopoietin-2 / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D015870:Gene Expression; D050438:Genes, Immunoglobulin Heavy Chain; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology*; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood / Q000378:metabolism; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D016019:Survival Analysis
chemical_list: D042702:Angiopoietin-2; D014408:Biomarkers, Tumor; D007135:Immunoglobulin Variable Region; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1